Therapeutic Advances in Gastroenterology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin
Conclusion: These results suggest that SBI improves clinical management of IBD patients who are not fully managed on traditional therapies. SBI should be considered for the nutritional support of IBD regardless of disease activity, location, phenotype, duration, or complexity. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - October 13, 2015 Category: Gastroenterology Authors: Shafran, I., Burgunder, P., Wei, D., Young, H. E., Klein, G., Burnett, B. P. Tags: Original Research Source Type: research

Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors
Conclusions: Across the 14-hour daytime period, esomeprazole 20 mg once daily given 30 minutes before breakfast for 5 days provided acid control for a significantly greater average proportion of time versus the PPI comparators omeprazole, pantoprazole and lansoprazole at currently available OTC dosages. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - October 13, 2015 Category: Gastroenterology Authors: Katz, P., Kahrilas, P. J., Johnson, D. A., Lind, T., Rohss, K., Traxler, B., Hugo, V., Dent, J. Tags: Original Research Source Type: research

Grasping forceps assisted endoloop/snare polypectomy of a giant duodenal hamartoma
(Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - July 13, 2015 Category: Gastroenterology Authors: Curcio, G., Ligresti, D., Granata, A., Tarantino, I., Barresi, L., Liotta, R., Traina, M. Tags: Letter to the Editor Source Type: research

The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment
Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world’s population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortality and all-cause mortality, being cured of CHC is associated with improvement in these outcomes. Older interferon-based regimens were complex and toxic and required 6–12 months of therapy, with cure rates averaging around 40–45% for HCV genotype 1. Newer interferon-free regimens are now availa...
Source: Therapeutic Advances in Gastroenterology - July 13, 2015 Category: Gastroenterology Authors: Lam, B. P., Jeffers, T., Younoszai, Z., Fazel, Y., Younossi, Z. M. Tags: Reviews Source Type: research

Management of regorafenib-related toxicities: a review
Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), RAF, KIT, RET and BRAF. Its antiangiogenic effect is greater than that of its related drug, sorafenib. Regorafenib has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC) in patients who have failed treatment with fluoropyrimidine, oxaliplatin and irinotecan base...
Source: Therapeutic Advances in Gastroenterology - July 13, 2015 Category: Gastroenterology Authors: Krishnamoorthy, S. K., Relias, V., Sebastian, S., Jayaraman, V., Saif, M. W. Tags: Reviews Source Type: research

The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective
AST-120 (kremezin) exhibits its favourable effects in reducing the levels of renal toxins by selective adsorption of low molecular weight substances from the intestinal lumen. So far, a vast majority of studies were focused on the role of AST-120 in the treatment of chronic kidney diseases and cardiovascular disorders, and positive therapeutic effects of the agent have already been confirmed in clinical conditions. Up to the present, there are only a few studies regarding the role of AST-120 in irritable bowel syndrome (IBS). Compelling data suggest the ability of the compound to adsorb protein-bound uremic toxins and mast...
Source: Therapeutic Advances in Gastroenterology - July 13, 2015 Category: Gastroenterology Authors: Mosinska, P., Storr, M., Fichna, J. Tags: Reviews Source Type: research

Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review
Irritable bowel syndrome (IBS) is notoriously difficult to treat and this situation is unlikely to change until the pathophysiology is better understood. There is no doubt that IBS is a multifactorial condition but it is likely that the relative contribution of the various factors involved varies from patient to patient. Consequently, in some individuals one mechanism may have such a strong effect that its elimination may lead to a substantial improvement in symptoms. This paper describes a patient with severe asthma and IBS where the administration of an anti-Immunoglobulin E (IgE) monoclonal antibody not only improved he...
Source: Therapeutic Advances in Gastroenterology - July 13, 2015 Category: Gastroenterology Authors: Pearson, J. S., Niven, R. M., Meng, J., Atarodi, S., Whorwell, P. J. Tags: Reviews Source Type: research

The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial)
Conclusions: These results demonstrated that education of CI sites unfamiliar with DAAs resulted in patient outcomes consistent with those observed at DAA-experienced academic sites. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - July 13, 2015 Category: Gastroenterology Authors: Poordad, F., Rustgi, V., Brown, R. S., Patel, V., Kugelmas, M., Regenstein, F., Balart, L., LaBrecque, D., Brown, K., Avila, M., Biederman, M., Freed, G., Smith, R., Bernstein, M., Arnold, H., Cahan, J., Fink, S., Katkov, W., Massoumi, H., Harrison, S. Tags: Original Research Source Type: research

Outcomes and precautions of endoscopic submucosal dissection for undifferentiated-type early gastric cancer
Conclusions: Undifferentiated-type EGC with a positive horizontal margin may relapse after ESD. It is therefore essential to precisely evaluate the area of the lesion and to perform resection with an adequate safety margin to decrease the risk of recurrence. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - July 13, 2015 Category: Gastroenterology Authors: Inokuchi, Y., Kobayashi, M., Kudo, K., Yamada, H., Inoue, S., Nishimura, K., Nakayama, N., Motohashi, O. Tags: Original Research Source Type: research

Polyethylene glycol plus an oral sulfate solution as a bowel cleansing regimen for colon capsule endoscopy: a prospective, single-arm study in healthy volunteers
Conclusions: A bowel cleansing regimen of PEG plus an oral sulfate solution can be used in healthy volunteers. These data provide support for the continued study of this regimen in future CCE clinical trials and in medical practice. (Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - July 13, 2015 Category: Gastroenterology Authors: Kashyap, P. K., Peled, R. Tags: Original Research Source Type: research

Endoscopic closure of gastrocutaneous fistula with an AMPLATZERTM septal occluder device
(Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - June 4, 2015 Category: Gastroenterology Authors: Odemis, B., Beyazit, Y., Torun, S., Kayacetin, E. Tags: Letters to the Editor Source Type: research

Conservative management of esophageal perforation due to external air-blast injury: a case report and literature review
(Source: Therapeutic Advances in Gastroenterology)
Source: Therapeutic Advances in Gastroenterology - June 4, 2015 Category: Gastroenterology Authors: Zhao, G.-j., Cheng, J.-y., Zhi, S.-c., Jin, X., Lu, Z.-q. Tags: Letters to the Editor Source Type: research

Choosing the optimal method in programmatic colorectal cancer screening: current evidence and controversies
Colorectal cancer (CRC) is an important health problem all over the world, being the third most common cancer and the second leading cause of cancer-related death in Western countries. The most important strategy for CRC prevention is screening (i.e. secondary prevention). Since it is widely accepted that adenomas and serrated polyps are the precursors of the vast majority of CRC, early detection and removal of these lesions is associated with a reduction of CRC incidence and, consequently, mortality. Moreover, cancers detected by screening are usually diagnosed at early stages and, therefore, curable by endoscopic or surg...
Source: Therapeutic Advances in Gastroenterology - June 4, 2015 Category: Gastroenterology Authors: Castells, A. Tags: Reviews Source Type: research

Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities
With the recent introduction and approval of medications directed at the treatment of opioid induced constipation (OIC) in patients with nonmalignant pain, there is increased interest and understanding of the unmet need and opportunities to enhance patient management. The high incidence of OIC is associated with rapid increase of narcotic analgesic prescriptions for nonmalignant chronic pain. This review addresses briefly the mechanisms of action of opioids that lead to OIC, the differential tolerance of gastrointestinal organs to the effects of opioids, the size and scope of the problem, the definition and outcome measure...
Source: Therapeutic Advances in Gastroenterology - June 4, 2015 Category: Gastroenterology Authors: Nelson, A. D., Camilleri, M. Tags: Reviews Source Type: research

Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
Adenocarcinomas of the esophagus and stomach are a major cause of cancer-related morbidity and mortality worldwide. For patients with advanced disease, first-line chemotherapy with platinum–fluoropyrimidine combinations prolongs survival, but inevitably the disease progresses with a median progression-free survival of approximately 6 months. At the time of progression, approximately 40–50% of patients remain fit and eligible for second-line treatment. Docetaxel has been extensively studied in this chemorefractory setting, mostly in small single arm studies, either as a single agent or in combination with platin...
Source: Therapeutic Advances in Gastroenterology - June 4, 2015 Category: Gastroenterology Authors: Ford, H., Gounaris, I. Tags: Reviews Source Type: research